CYP4F2
Cytochrome P450 Family 4 Subfamily F Member 2
Gene Information Card
| Symbol | CYP4F2 |
|---|---|
| Full Name | Cytochrome P450 Family 4 Subfamily F Member 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 19p13.12 |
| NCBI Gene ID | 8529 ncbi.nlm.nih.gov/gene/8529 |
| Ensembl ID | ENSG00000186115 |
| UniProt ID | Q9H4B8 |
| OMIM ID | 604426 |
| HGNC ID | 2645 |
| Aliases | CPF2, CYP4F, CYP4F2*1, CYPIVF2 |
Description
CYP4F2 encodes a member of the cytochrome P450 family 4, subfamily F. This enzyme is involved in the metabolism of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) and in the oxidation of vitamin K1 (phylloquinone) and vitamin K2 (menaquinone). It plays a critical role in blood pressure regulation and vitamin K homeostasis, influencing coagulation and bone metabolism.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hypertension | Reduced 20-HETE production due to loss-of-function variants may impair renal sodium excretion and vascular tone. | PMID: 18757876 |
| Warfarin sensitivity | Impaired vitamin K oxidation leads to lower clotting factor synthesis, increasing warfarin effect. | PMID: 18305455 |
| Cardiovascular disease | Altered 20-HETE levels contribute to endothelial dysfunction and atherosclerosis risk. | PMID: 21536671 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.5 | Medium |
| Kidney | 8.3 | Medium |
| Small intestine | 6.1 | Low |
| Lung | 4.2 | Low |
| Heart | 2.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 10.1 | Hepatocyte-derived |
| HK-2 | 7.5 | Kidney proximal tubule |
| Caco-2 | 5.3 | Colorectal adenocarcinoma |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| rs2108622 (V433M) | Missense | ~7-15% (European) | Reduced catalytic activity; associated with warfarin dose requirement |
| rs3093105 (W12G) | Missense | ~2-5% (African) | Decreased 20-HETE production; linked to hypertension risk |
Mutation functional classification
Loss of Function (LOF)
rs2108622 (V433M) reduces enzyme activity for vitamin K and arachidonic acid metabolism.
Gain of Function (GOF)
No well-characterized gain-of-function variants reported.
Dominant Negative (DN)
Not described for CYP4F2.
View complete mutation data：
Gene Ontology (GO)
| • arachidonic acid epoxygenase activity | • heme binding |
| • iron ion binding | • oxidoreductase activity |
| • vitamin K1 catabolic process |
Pathways
• Arachidonic acid metabolism
• Vitamin K metabolism
• Cytochrome P450 - xenobiotic metabolism
Protein Summary
CYP4F2 is a microsomal cytochrome P450 monooxygenase that catalyzes the omega-hydroxylation of arachidonic acid to 20-HETE and the oxidation of vitamin K. It is highly expressed in liver and kidney. Genetic variants, particularly V433M, affect warfarin dosing and blood pressure regulation.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CYP4F2 Knockout HEK293 Cell Line | EDJ-KQ6270 | Human | 8529 | Details Get a Quote |
| CYP4F22 Knockout HEK293 Cell Line | EDJ-KQ8916 | Human | 126410 | Details Get a Quote |
| CYP4F22 Knockout HCT 116 Cell Line | EDJ-KQ35257 | Human | 126410 | Details Get a Quote |
| CYP4F2 Knockout HeLa Cell Line | EDJ-KQ54931 | Human | 8529 | Details Get a Quote |
| CYP4F22 Knockout HeLa Cell Line | EDJ-KQ58177 | Human | 126410 | Details Get a Quote |
| CYP4F2 Knockout A-549 Cell Line | EDJ-KQ63417 | Human | 8529 | Details Get a Quote |
| CYP4F22 Knockout A-549 Cell Line | EDJ-KQ66666 | Human | 126410 | Details Get a Quote |
| CYP4F2 Knockout HCT 116 Cell Line | EDJ-KQ71881 | Human | 8529 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
